Q2 FY26 · Ended Jun 30, 2026 · View SEC filing
A franchise shrank sharply, yet total sales held
Dermatology lost 15.9% of its sales, yet parasiticides, vaccines, anti-infectives and diagnostics held total revenue almost flat.
For investorsCan the growing lines keep covering the dermatology decline?
For foundersSelling through the expert who recommends
Net income fell 4.8%, yet diluted earnings per share rose because the share count shrank after buybacks.
Free cash flow was $538M against $459M a year earlier, as capital spending fell and more profit turned into cash.
Charges rose to $77M from $30M, roughly the amount by which pretax income fell, while overhead costs declined.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Zoetis from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
